Breaking News Instant updates and real-time market news.

2022-05-26 10:19:45 RVVTF Revive Therapeutics / + 10:19 05/26/22 05/26 10:19 05/26/22 10:19	Revive Therapeutics provides update on Phase 3 trial for bucillamine in COVID-19 Revive Therapeutics is pleased to provide an update on the Company's U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The Company has received positive comments from the FDA in regards to the Company's request to determine and agree on the Study's potential new primary efficacy endpoints, including the rate of sustained clinical resolution of symptoms of COVID-19, which addresses the shift in COVID-19 clinical outcome observed over the course of the pandemic, and, therefore, to have more meaningful study endpoints for the FDA to consider for potential Emergency Use Authorization. The FDA has agreed that the Company may unblind the pre-dose-selection data for the first 210 patients of the Study to further support the new primary endpoint. Before unblinding the pre-dose selection data for the first 210 patients, the Company will submit a Data Access Plan to the FDA in early June 2022 with the aim to unblind the pre-dose selection data and submit the amended Study protocol with the new primary efficacy endpoints to the FDA. In addition, the Data Safety and Monitoring Board are scheduled to meet thereafter to evaluate the interim clinical and safety data and may make a recommendation on continuing the Study or advise on halting the Study early due to positive efficacy based on other clinical outcomes such as the rate of sustained clinical resolution of symptoms of COVID-19. The DSMB supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported.

2022-05-26 10:19:45

RVVTF

Revive Therapeutics

/ +

10:19

05/26/22

05/26

10:19

05/26/22

10:19

Revive Therapeutics provides update on Phase 3 trial for bucillamine in COVID-19

Revive Therapeutics is pleased to provide an update on the Company's U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The Company has received positive comments from the FDA in regards to the Company's request to determine and agree on the Study's potential new primary efficacy endpoints, including the rate of sustained clinical resolution of symptoms of COVID-19, which addresses the shift in COVID-19 clinical outcome observed over the course of the pandemic, and, therefore, to have more meaningful study endpoints for the FDA to consider for potential Emergency Use Authorization. The FDA has agreed that the Company may unblind the pre-dose-selection data for the first 210 patients of the Study to further support the new primary endpoint. Before unblinding the pre-dose selection data for the first 210 patients, the Company will submit a Data Access Plan to the FDA in early June 2022 with the aim to unblind the pre-dose selection data and submit the amended Study protocol with the new primary efficacy endpoints to the FDA. In addition, the Data Safety and Monitoring Board are scheduled to meet thereafter to evaluate the interim clinical and safety data and may make a recommendation on continuing the Study or advise on halting the Study early due to positive efficacy based on other clinical outcomes such as the rate of sustained clinical resolution of symptoms of COVID-19. The DSMB supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported.

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Rogers Sugar price target raised to C$6.50 from C$6 at Scotiabank » 12:10 08/12/22 08/12 12:10 08/12/22 12:10 RSGUF Rogers Sugar $5.03 / +0.065 (+1.31%) Scotiabank analyst George… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings RSGUF Rogers Sugar $5.03 / +0.065 (+1.31%) 08/11/22 Rogers Sugar expects improved financial performance in 2022 RSGUF Rogers Sugar $5.03 / +0.065 (+1.31%) 05/04/22 National Bank Rogers Sugar price target raised to C$5.75 from C$5.25 at National Bank 02/11/22 BMO Capital Rogers Sugar price target raised to C$6.50 from C$6 at BMO Capital 11/30/21 Desjardins Rogers Sugar price target raised to C$6 from C$5.75 at Desjardins 11/26/21 BMO Capital Rogers Sugar price target raised to C$6 from C$5.75 at BMO Capital RSGUF Rogers Sugar $5.03 / +0.065 (+1.31%) 08/11/22 Rogers Sugar reports Q3 adjusted EPS C$0.08 vs. C$0.04 last year 05/12/22 Rogers Sugar reports Q2 adjusted EPS C$0.09 vs. C$0.07 last year
Recommendations	Onex price target lowered to C$105 from C$118 at Scotiabank » 12:10 08/12/22 08/12 12:10 08/12/22 12:10 ONEXF Onex $54.83 / +0.04 (+0.07%) Scotiabank analyst Phil… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings ONEXF Onex $54.83 / +0.04 (+0.07%) 07/05/22 ONCAP makes investment in Ideal Dental 06/08/22 Gluskin Sheff launches Onex Partners Private Equity Solution 2022 05/26/22 Ryan to receive investments from Onex, Ares Management 04/13/22 Onex files normal course issuer bid ONEXF Onex $54.83 / +0.04 (+0.07%) 07/28/22 Canaccord Onex price target lowered to C$91 from C$104 at Canaccord 05/16/22 Canaccord Onex price target lowered to C$104 from C$110 at Canaccord 05/16/22 RBC Capital Onex price target raised to C$110 from C$108 at RBC Capital 05/16/22 TD Securities Onex price target raised to C$115 from C$110 at TD Securities ONEXF Onex $54.83 / +0.04 (+0.07%) 08/11/22 Onex reports Q2 EPS ($2.15) vs. $1.95 last year 02/25/22 Onex reports Q4 segment EPS $3.65 vs. $7.72 last year
Recommendations	Kits Eyecare price target lowered to C$3.50 from C$5 at Scotiabank » 12:09 08/12/22 08/12 12:09 08/12/22 12:09 KTYCF Kits Eyecare $2.32 / +0.49 (+26.78%) Scotiabank analyst George… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KTYCF Kits Eyecare $2.32 / +0.49 (+26.78%) 05/12/22 Canaccord Kits Eyecare price target lowered to C$7 from C$8 at Canaccord 11/17/21 Canaccord Kits Eyecare price target lowered to C$8 from C$11 at Canaccord 11/17/21 Scotiabank Kits Eyecare price target lowered to C$5 from C$7.50 at Scotiabank 08/13/21 Scotiabank Kits Eyecare price target lowered to C$7.50 from C$10.50 at Scotiabank
Recommendations	KP Tissue price target lowered to C$11 from C$11.50 at Scotiabank » 12:09 08/12/22 08/12 12:09 08/12/22 12:09 KPTSF KP Tissue $7.90 / + (+0.00%) Scotiabank analyst Benoit… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings KPTSF KP Tissue $7.90 / + (+0.00%) 08/11/22 KP Tissue anticipates momentum in Q3 revenue for Consumer, AFH 03/10/22 KP Tissue sees Q1 adjusted EBITDA C$30M-C$35M KPTSF KP Tissue $7.90 / + (+0.00%) 11:55 Today TD Securities KP Tissue price target lowered to C$10.50 from C$11.50 at TD Securities 05/13/22 RBC Capital KP Tissue price target lowered to C$10 from C$11 at RBC Capital 03/11/22 RBC Capital KP Tissue downgraded to Sector Perform from Outperform at RBC Capital 11/16/21 Desjardins KP Tissue price target lowered to C$11 from C$11.50 at Desjardins KPTSF KP Tissue $7.90 / + (+0.00%) 08/11/22 KP Tissue reports Q2 EPS (C$0.40) vs. (C$0.13) last year 05/12/22 KP Tissue reports Q1 EPS C$0.10c vs C$0.12c last year 03/10/22 KP Tissue reports Q4 EPS C$0.35 vs. (C$0.44) last year
Recommendations	Dialogue Health price target lowered to C$8 from C$8.50 at Scotiabank » 12:08 08/12/22 08/12 12:08 08/12/22 12:08 DLHTF Dialogue Health $2.30 / + (+0.00%) Scotiabank analyst Adam… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research DLHTF Dialogue Health $2.30 / + (+0.00%) 11:55 Today TD Securities Dialogue Health price target lowered to C$4.50 from C$5.50 at TD Securities 08/09/22 National Bank Dialogue Health price target lowered to C$8.50 from C$11.50 at National Bank
Recommendations	Chemtrade Logistics price target raised to C$10.50 from C$10.25 at Scotiabank » 12:07 08/12/22 08/12 12:07 08/12/22 12:07 CGIFF Chemtrade Logistics $7.11 / +0.5 (+7.56%) Scotiabank analyst Ben… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research CGIFF Chemtrade Logistics $7.11 / +0.5 (+7.56%) 06/27/22 Scotiabank Chemtrade Logistics upgraded to Outperform from Sector Perform at Scotiabank 05/12/22 Scotiabank Chemtrade Logistics price target raised to C$9.50 from C$8.50 at Scotiabank 05/11/22 BMO Capital Chemtrade Logistics price target raised to C$8 from C$7.50 at BMO Capital 05/11/22 National Bank Chemtrade Logistics price target raised to C$9.25 from C$8.75 at National Bank
Recommendations	Badger Infrastructure price target lowered to C$38 from C$40 at Scotiabank » 12:05 08/12/22 08/12 12:05 08/12/22 12:05 BADFF Badger Infrastructure $25.24 / +0.74 (+3.02%) Scotiabank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BADFF Badger Infrastructure $25.24 / +0.74 (+3.02%) 11:53 Today TD Securities Badger Infrastructure price target raised to C$34 from C$33 at TD Securities 05/16/22 CIBC Badger Infrastructure price target raised to C$31.50 from C$30 at CIBC 05/16/22 Stifel Badger Infrastructure price target raised to C$35 from C$34.50 at Stifel 05/16/22 Scotiabank Badger Infrastructure price target raised to C$40 from C$39 at Scotiabank
Recommendations	Antofagasta price target lowered to 1,250 GBp from 1,300 GBp at Scotiabank » 12:05 08/12/22 08/12 12:05 08/12/22 12:05 ANFGF Antofagasta $13.25 / + (+0.00%) Scotiabank analyst Orest… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research ANFGF Antofagasta $13.25 / + (+0.00%) 07/29/22 RBC Capital Antofagasta upgraded to Sector Perform from Underperform at RBC Capital 07/21/22 JPMorgan Antofagasta price target lowered to 1,460 GBp from 1,480 GBp at JPMorgan 07/21/22 RBC Capital Antofagasta price target lowered to 1,000 GBp from 1,050 GBp at RBC Capital 07/19/22 Morgan Stanley Antofagasta price target lowered to 1,320 GBp from 1,370 GBp at Morgan Stanley
Recommendations	Illumina price target lowered to $240 from $350 at Morgan Stanley » 12:04 08/12/22 08/12 12:04 08/12/22 12:04 ILMN Illumina $207.96 / -19.68 (-8.65%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ILMN Illumina $207.96 / -19.68 (-8.65%) 08/11/22 Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5% 08/11/22 Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut 06/09/22 Illumina drops 6% to $210.00 after departure of CFO 06/09/22 Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO ILMN Illumina $207.96 / -19.68 (-8.65%) 09:17 Today BofA Illumina price target lowered to $200 from $220 at BofA 08:45 Today Piper Sandler Piper a buyer of Illumina weakness ahead of Genomics Forum 07:44 Today Canaccord Illumina price target lowered to $380 from $450 at Canaccord 07:16 Today Stifel Illumina price target lowered to $300 from $480 at Stifel ILMN Illumina $207.96 / -19.68 (-8.65%) 08/11/22 Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20 08/11/22 Illumina reports Q2 adjusted EPS 57c, consensus 65c 08/11/22 Notable companies reporting after market close 05/05/22 Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15 ILMN Illumina $207.96 / -19.68 (-8.65%) 07/27/22 Illumina's Grail deal likely to be blocked by EU regulators, Reuters reports 07/13/22 Illumina lost bid to block EU watchdog review of Grail deal, Bloomberg reports ILMN Illumina $207.96 / -19.68 (-8.65%) 08:59 Today Fly Intel: Pre-market Movers 08/11/22 Fly Intel: After-Hours Movers 07/13/22 What You Missed On Wall Street On Wednesday 07/13/22 What You Missed On Wall Street This Morning 09/10/22 ESMO Congress 2022 ILMN Illumina $207.96 / -19.68 (-8.65%) 08/11/22 Illumina options imply 6.5% move in share price post-earnings 06/13/22 Illumina put buyer realizes 25% same-day gains 05/18/22 Early notable gainers among liquid option names on May 18th
Recommendations	AG Growth International price target raised to C$55 from C$52 at Scotiabank » 12:04 08/12/22 08/12 12:04 08/12/22 12:04 AGGZF AG Growth International $29.81 / +3.80715 (+14.64%) Scotiabank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research AGGZF AG Growth International $29.81 / +3.80715 (+14.64%) 04/20/22 Scotiabank AG Growth International price target raised to C$52 from C$50 at Scotiabank 03/17/22 RBC Capital AG Growth International price target raised to C$50 from C$45 at RBC Capital 03/11/22 National Bank AG Growth International price target raised to C$49 from C$46 at National Bank 03/11/22 Desjardins AG Growth International price target raised to C$53 from C$49 at Desjardins

Recommendations	Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler » 12:02 08/12/22 08/12 12:02 08/12/22 12:02 HUMA Humacyte $4.44 / +0.06 (+1.37%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HUMA Humacyte $4.44 / +0.06 (+1.37%) 07/19/22 Humacyte announces presentation of preclinical data on HAV 07/07/22 Humacyte to host KOL webinar on Human Acellular Vessels 06/29/22 Humacyte announces JAMA Surgery publication on HAV's potential 06/21/22 Humacyte provides update on patients treated with HAV in Ukraine HUMA Humacyte $4.44 / +0.06 (+1.37%) 07/18/22 BTIG Humacyte price target lowered to $10 from $12 at BTIG 05/15/22 Piper Sandler Humacyte downgraded to Underweight from Overweight at Piper Sandler 03/29/22 Piper Sandler Humacyte price target lowered to $10 from $17 at Piper Sandler 10/29/21 Cowen Humacyte initiated with an Outperform at Cowen HUMA Humacyte $4.44 / +0.06 (+1.37%) 07:03 Today Humacyte reports Q2 EPS 35c, consensus (22c) 05/13/22 Humacyte reports Q1 EPS (19c), consensus (21c) 03/29/22 Humacyte reports Q4 EPS 41c, consensus (20c) HUMA Humacyte $4.44 / +0.06 (+1.37%) 05/16/22 What You Missed On Wall Street On Monday 05/16/22 What You Missed On Wall Street This Morning 08:00 Today Humacyte - HUMA
Hot Stocks	SmartRent falls -32.7% » 12:00 08/12/22 08/12 12:00 08/12/22 12:00 SMRT SmartRent $3.78 / -1.785 (-32.10%) SmartRent is down -32.7%,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SMRT SmartRent $3.78 / -1.785 (-32.10%) 10:00 Today SmartRent falls -26.6% 09:47 Today SmartRent falls -19.5% 08/11/22 SmartRent falls 28% to $4.02 after Q2 earnings miss and guidance cut 05/17/22 SmartRent director buys $1.04M in common stock SMRT SmartRent $3.78 / -1.785 (-32.10%) 08:15 Today Cantor Fitzgerald SmartRent price target lowered to $5.25 from $6.00 at Cantor Fitzgerald 07/22/22 Cantor Fitzgerald SmartRent assumed with an Overweight at Cantor Fitzgerald 07/19/22 Keefe Bruyette Bain Capital sold 5% of stake in SmartRent, says Keefe Bruyette 05/25/22 Compass Point Compass Point starts SmartRent at Buy, sees 'exponential growth potential' SMRT SmartRent $3.78 / -1.785 (-32.10%) 08/11/22 SmartRent cuts FY22 revenue view to $155M-$180M from $220M-$250M 08/11/22 SmartRent sees Q3 revenue $43M-$47M, consensus $75.4M 08/11/22 SmartRent reports Q2 EPS (13c), consensus (11c) 05/11/22 SmartRent sees FY22 revenue $220M-$250M, consensus $238.1M SMRT SmartRent $3.78 / -1.785 (-32.10%) 08/11/22 Fly Intel: After-Hours Movers 05/11/22 Fly Intel: After-Hours Movers 03/24/22 Fly Intel: After-Hours Movers 02/15/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Olo falls -33.8% » 12:00 08/12/22 08/12 12:00 08/12/22 12:00 OLO Olo $8.60 / -4.42 (-33.95%) Olo is down -33.8%, or… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly OLO Olo $8.60 / -4.42 (-33.95%) 10:00 Today Olo falls -27.6% 09:47 Today Olo falls -32.1% 05/10/22 Olo appoints Diego Panama as chief revenue officer 04/14/22 Olo, SOCi partner for SOCi integration with Olo API OLO Olo $8.60 / -4.42 (-33.95%) 09:24 Today RBC Capital Olo price target lowered to $12 from $17 at RBC Capital 09:07 Today Truist Olo price target lowered to $16 from $25 at Truist 05:47 Today Piper Sandler Olo downgraded to Neutral from Overweight at Piper Sandler 05:26 Today Stifel Olo downgraded to Hold from Buy at Stifel OLO Olo $8.60 / -4.42 (-33.95%) 08/11/22 Olo cuts FY22 revenue view to $183M-$184M, consensus $195.6M 08/11/22 Olo sees Q3 revenue $46.5M-$47.0M, consensus $51.1M 08/11/22 Olo reports Q2 EPS 1c, consensus 0c 05/10/22 Olo sees Q2 revenue $45.5M-$46M, consensus $45.48M OLO Olo $8.60 / -4.42 (-33.95%) 09:34 Today Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/11/22 Fly Intel: After-Hours Movers
Hot Stocks	CS Disco falls -54.0% » 12:00 08/12/22 08/12 12:00 08/12/22 12:00 LAW CS Disco $13.35 / -15.61 (-53.90%) CS Disco is down -54.0%,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $13.35 / -15.61 (-53.90%) 10:00 Today CS Disco falls -51.9% 09:47 Today CS Disco falls -48.4% 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% LAW CS Disco $13.35 / -15.61 (-53.90%) 07:45 Today Canaccord CS Disco downgraded to Hold at Canaccord as estimates get reset 07:15 Today Stifel CS Disco price target lowered to $30 from $40 at Stifel 06:15 Today BofA CS Disco downgraded to Neutral from Buy at BofA 06:05 Today Canaccord CS Disco downgraded to Hold from Buy at Canaccord LAW CS Disco $13.35 / -15.61 (-53.90%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $13.35 / -15.61 (-53.90%) 09:34 Today Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08:59 Today Fly Intel: Pre-market Movers 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Hot Stocks	ESS Inc. rises 17.5% » 12:00 08/12/22 08/12 12:00 08/12/22 12:00 GWH ESS Inc. $4.91 / +0.725 (+17.32%) ESS Inc. is up 17.5%, or… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings GWH ESS Inc. $4.91 / +0.725 (+17.32%) 10:00 Today ESS Inc. rises 14.6% 09:47 Today ESS Inc. rises 10.0% 08/11/22 ESS Inc. announces partnership to deploy long-term energy storage in Australia 03/24/22 ESS Inc. rises 10.9% GWH ESS Inc. $4.91 / +0.725 (+17.32%) 07/13/22 Canaccord ESS Inc. assumed with a Hold at Canaccord 06/29/22 Chardan ESS Inc. initiated with a Neutral at Chardan 03/30/22 Deutsche Bank ESS Inc. initiated with a Hold at Deutsche Bank 03/22/22 Guggenheim Guggenheim starts ESS Inc. at Buy on flow battery odds of success GWH ESS Inc. $4.91 / +0.725 (+17.32%) 08/11/22 ESS Inc. reports Q2 EPS (10c), consensus (15c) 05/12/22 ESS Inc. reports Q1 EPS (4c), consensus (13c) 02/24/22 ESS Inc. reports Q4 EPS ($1.33) vs. (41c) last year
Hot Stocks	Xponential Fitness rises 21.1% » 12:00 08/12/22 08/12 12:00 08/12/22 12:00 XPOF Xponential Fitness $19.65 / +3.42 (+21.07%) Xponential Fitness is up… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly XPOF Xponential Fitness $19.65 / +3.42 (+21.07%) 10:00 Today Xponential Fitness rises 22.6% 08/01/22 Xponential Fitness signs master franchise agreement in Japan for CycleBar 07/27/22 Xponential Fitness reports Q2 system-wide sales to $250M up 45% from last year 05/10/22 Xponential Fitness in franchise pact in Mexico for three brands XPOF Xponential Fitness $19.65 / +3.42 (+21.07%) 06/13/22 Jefferies Jefferies names five top picks in lifestyle and growth platforms 03/14/22 Evercore ISI Evercore ISI starts Xponential Fitness at Outperform with $34 price target 03/14/22 Evercore ISI Xponential Fitness initiated with an Outperform at Evercore ISI 03/14/22 Baird Xponential Fitness price target raised to $28 from $26 at Baird XPOF Xponential Fitness $19.65 / +3.42 (+21.07%) 08/11/22 Xponential Fitness raises FY22 revenue view to $211M-$221M from $201M-$211M 08/11/22 Xponential Fitness reports Q2 EPS 50c 05/12/22 Xponential Fitness backs FY22 revenue $201M-$211M, consensus $209.85M 05/12/22 Xponential Fitness reports Q1 adjusted EPS (19c), consensus 12c 07 Apr XPOF Xponential Fitness $19.65 / +3.42 (+21.07%) 04/05/22 What You Missed On Wall Street This Morning 04/05/22 Fly Intel: Pre-market Movers 04/04/22 Fly Intel: After-Hours Movers
Hot Stocks	Invitae rises 29.0% » 12:00 08/12/22 08/12 12:00 08/12/22 12:00 NVTA Invitae $5.81 / +1.28 (+28.29%) Invitae is up 29.0%, or… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options NVTA Invitae $5.81 / +1.28 (+28.29%) 10:00 Today Invitae rises 20.6% 08/11/22 Invitae falls -42.9% 08/11/22 Invitae falls -39.0% 08/11/22 Invitae falls -25.4% NVTA Invitae $5.81 / +1.28 (+28.29%) 08/10/22 JPMorgan Invitae cut to Underweight at JPMorgan with future growth yet to be proven 08/10/22 JPMorgan Invitae downgraded to Underweight from Neutral at JPMorgan 07/26/22 Cowen Invitae cut to Market Perform at Cowen on debt refinancing uncertainty 07/26/22 Cowen Invitae downgraded to Market Perform from Outperform at Cowen NVTA Invitae $5.81 / +1.28 (+28.29%) 08/09/22 Invitae backs FY22 revenue growth of low double digits, consensus $542.96M 08/09/22 Invitae reports Q2 adjusted EPS (68c), consensus (76c) 07/18/22 Invitae sees second half of FY22 revenue flat over first half of FY22 07/18/22 Invitae sees Q2 revenue $136M, consensus $142.74M NVTA Invitae $5.81 / +1.28 (+28.29%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 07/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 Fly Intel: After-Hours Movers 09/10/22 ESMO Congress 2022 NVTA Invitae $5.81 / +1.28 (+28.29%) 09:40 Today Unusually active option classes on open August 12th 08/11/22 Invitae call buyer realizes 3500% same-day gains 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings
Recommendations	Savaria price target raised to C$20 from C$19 at TD Securities » 11:59 08/12/22 08/12 11:59 08/12/22 11:59 SISXF Savaria $11.34 / + (+0.00%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research SISXF Savaria $11.34 / + (+0.00%) 07/19/22 Scotiabank Savaria price target lowered to C$16.50 from C$20 at Scotiabank 05/16/22 Desjardins Savaria price target lowered to C$25 from C$25.50 at Desjardins 05/13/22 Scotiabank Savaria price target lowered to C$20 from C$21 at Scotiabank 05/13/22 TD Securities Savaria price target lowered to C$19 from C$22 at TD Securities
Recommendations	Peyto Exploration price target lowered to C$18.50 from C$19 at TD Securities » 11:59 08/12/22 08/12 11:59 08/12/22 11:59 PEYUF Peyto Exploration $10.61 / -0.19 (-1.76%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research PEYUF Peyto Exploration $10.61 / -0.19 (-1.76%) 08/11/22 National Bank Peyto Exploration price target lowered to C$19 from C$19.50 at National Bank 07/18/22 National Bank Peyto Exploration price target lowered to C$19.50 from C$23 at National Bank 07/14/22 Scotiabank Peyto Exploration price target raised to C$24 from C$23 at Scotiabank 06/30/22 Stifel Peyto Exploration price target lowered to C$19.25 from C$20 at Stifel
Recommendations	Killam Apartment REIT price target raised to C$22 from C$21 at TD Securities » 11:59 08/12/22 08/12 11:59 08/12/22 11:59 KMMPF Killam Apartment REIT $14.20 / +0.77 (+5.73%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research KMMPF Killam Apartment REIT $14.20 / +0.77 (+5.73%) 07/20/22 National Bank Killam Apartment price target lowered to C$19.25 from C$25 at National Bank 05/09/22 Raymond James Killam Apartment REIT price target lowered to C$24 from C$27 at Raymond James 05/09/22 Desjardins Killam Apartment REIT price target lowered to C$25 from C$26 at Desjardins 05/06/22 Canaccord Killam Apartment REIT price target lowered to C$23.50 from C$25.50 at Canaccord

Recommendations	Goeasy price target raised to C$200 from C$195 at TD Securities » 11:58 08/12/22 08/12 11:58 08/12/22 11:58 EHMEF Goeasy $110.36 / +8.68514 (+8.54%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research EHMEF Goeasy $110.36 / +8.68514 (+8.54%) 07/19/22 Goeasy appoints Jonathan Tetrault to board of directors 07/05/22 Goeasy announces $500M increase to securitization facility EHMEF Goeasy $110.36 / +8.68514 (+8.54%) 08/11/22 National Bank Goeasy price target raised to C$170 from C$155 at National Bank 08/04/22 TD Securities Goeasy price target lowered to C$195 from C$215 at TD Securities 07/20/22 Scotiabank Goeasy price target lowered to C$140 from C$160 at Scotiabank 07/08/22 Raymond James Goeasy price target lowered to C$202 from C$213 at Raymond James
Recommendations	Canadian Apartment Properties price target raised to C$60 at TD Securities » 11:58 08/12/22 08/12 11:58 08/12/22 11:58 CDPYF Canadian Apartment Properties $37.23 / -0.85 (-2.23%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research CDPYF Canadian Apartment Properties $37.23 / -0.85 (-2.23%) 06/30/22 Canadian Apartment Properties appoints Julian Schonfeldt as CIO 05/02/22 Canadian Apartment Properties purchases 172-site MHC in Alberta CDPYF Canadian Apartment Properties $37.23 / -0.85 (-2.23%) 07/20/22 National Bank CAP REIT price target lowered to C$50 from C$62.25 at National Bank 05/19/22 Desjardins Canadian Apartment Properties price target lowered to C$65 at Desjardins 05/19/22 Scotiabank Canadian Apartment Properties price target lowered to C$63 at Scotiabank 05/18/22 Raymond James Canadian Apartment Properties price target lowered to C$66 at Raymond James
Recommendations	Vermilion Energy price target raised to C$45 from C$40 at TD Securities » 11:57 08/12/22 08/12 11:57 08/12/22 11:57 VET Vermilion Energy $25.05 / -1.16 (-4.43%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options VET Vermilion Energy $25.05 / -1.16 (-4.43%) 08/11/22 Vermilion Energy raises quarterly dividend 33% to C$0.08 per share 04/26/22 Vermilion announces ISS, Glass Lewis recommend shareholders vote for resolutions 04/19/22 Vermilion Energy to issue $400M senior unsecured notes 03/28/22 Vermilion Energy raises FY22 production view to 86,000-88,000 boe/d VET Vermilion Energy $25.05 / -1.16 (-4.43%) 07/18/22 National Bank Vermilion Energy price target lowered to C$48 from C$52 at National Bank 07/14/22 Scotiabank Vermilion Energy price target raised to C$38 from C$36 at Scotiabank 06/30/22 Stifel Vermilion Energy upgraded to Buy from Hold at Stifel 06/27/22 Scotiabank Vermilion Energy upgraded to Outperform from Sector Perform at Scotiabank VET Vermilion Energy $25.05 / -1.16 (-4.43%) 03/07/22 Vermilion Energy reports Q4 diluted FFO $1.93 vs Q3 diluted FFO $1.59 VET Vermilion Energy $25.05 / -1.16 (-4.43%) 06/27/22 What You Missed On Wall Street On Monday 06/27/22 What You Missed On Wall Street This Morning 03/28/22 What You Missed On Wall Street On Monday 03/28/22 What You Missed On Wall Street This Morning 09:00 Today Vermilion Energy - VET VET Vermilion Energy $25.05 / -1.16 (-4.43%) 06/14/22 Vermilion Energy call volume above normal and directionally bullish 06/10/22 Vermilion Energy call volume above normal and directionally bullish 06/06/22 Vermilion Energy call volume above normal and directionally bullish 04/25/22 Vermilion Energy put volume heavy and directionally bearish
Recommendations	OverActive Media price target lowered to C$1.50 from C$2 at TD Securities » 11:57 08/12/22 08/12 11:57 08/12/22 11:57 OAMCF OverActive Media / + TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research OAMCF OverActive Media / + 06/21/22 OverActive Media announces changes to MAD Lions leadership team 06/16/22 OverActive Media, TD Bank expand sponsorship with multiyear agreement 06/02/22 OverActive Media, Bell announce multiyear extension of partnership 04/21/22 OverActive Media brings first Call of Duty League Major tournament to Canada OAMCF OverActive Media / + 01/07/22 TD Securities OverActive Media initiated with a Speculative Buy at TD Securities
Recommendations	Next Hydrogen Solutions price target raised to C$5.50 from C$4 at TD Securities » 11:56 08/12/22 08/12 11:56 08/12/22 11:56 NXHSF Next Hydrogen Solutions $1.30 / + (+0.00%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NXHSF Next Hydrogen Solutions $1.30 / + (+0.00%) 06/22/22 Next Hydrogen Solutions announces results of annual general meeting 05/02/22 Next Hydrogen Solutions announces upgrade to OTCQX 05/02/22 OTC Markets Group welcomes Next Hydrogen Solutions to OTCQX 04/07/22 Next Hydrogen signs MOU with Black & Veatch for green hydrogen solutions NXHSF Next Hydrogen Solutions $1.30 / + (+0.00%) 05/17/22 National Bank Next Hydrogen Solutions price target lowered to C$2.50 at National Bank 04/05/22 National Bank Next Hydrogen price target lowered to C$4.50 from C$6 at National Bank 01/11/22 National Bank Next Hydrogen Solutions price target lowered to C$6 from C$7 at National Bank 10/25/21 National Bank Next Hydrogen Solutions initiated with a Sector Perform at National Bank NXHSF Next Hydrogen Solutions $1.30 / + (+0.00%) 08/11/22 Next Hydrogen Solutions reports Q2 revenue C$44,826 vs. C$59,123 last year 05/16/22 Next Hydrogen Solutions reports Q1 revenue C$40,795 vs. C$0 last year 04/04/22 Next Hydrogen Solutions reports Q4 revenue $41,069 vs. $0 last year

Events

Earnings calls, analyst events, roadshows and more

ADMP
Today at 13:00

Adamis Pharmaceuticals Corporation Firm Sponsored Meetings
SNDA
Today at 13:30

Sonida Senior Living - SNDA Conference Calls
BEEM
Today at 16:30

Beam Global - BEEM Conference Calls
VORB
Today at 16:30

Virgin Orbit - VORB Conference Calls
BOC
Tomorrow at 10:00

Boston Omaha Corporation Firm Sponsored Meetings

3701 S 10th St, Omaha, NE
ECL ...
2022-08-15 at 00:00

GII Bus Tour Conferences

Minneapolis, MN
AERI ...
2022-08-15 at 00:00

2022 Biotech Summer Summit Conferences

Newport, RI
2022-08-15 at 00:00

7th Annual Virtual Med Tech & Diagnostics 1:1 Conference Conferences

Virtual Conference
PZZA
2022-08-15 at 00:00

Papa John's Firm Sponsored Meetings

Virtual Meeting
CBIO
2022-08-15 at 00:00

Catalyst Biosciences, Inc. Firm Sponsored Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley Priced at: $17.75 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Revive Therapeutics provides update on Phase 3 trial for bucillamine in COVID-19

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access